76 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
with this offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
We … financial statement closing procedures. The preliminary financial data included in this prospectus supplement has been prepared by, and is the responsibility
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
We are offering … closing procedures. The preliminary financial data included in this prospectus supplement has been prepared by, and is the responsibility of, our
8-K
EX-10.1
ubts2147xrl kwz5d016
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-3ASR
9dl8vbxbs ib
2 Jan 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.3
v5qz fnts00ny
2 Jan 24
Automatic shelf registration
4:06pm
CORRESP
299q9l6mtdttwgz0f4
27 Oct 23
Correspondence with SEC
12:00am
8-K
EX-1.2
yhs9pg8btznq40gp
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
f2goham8zn9habsuh
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
1s3nvhe8usqgisqe
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
ow0gaq3w
27 Sep 23
Prospectus supplement for primary offering
5:26pm